US · PCRX
Pacira BioSciences, Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Tampa, FL 33609
- Website
- pacira.com
Price · as of 2025-12-31
$24.44
Market cap 942.6M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $51.98 | +112.68% |
| Intrinsic Value(DCF) | $8.51 | -65.18% |
| Graham-Dodd Method(GD) | $18.10 | -25.96% |
| Graham Formula(GF) | $6.94 | -71.61% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $11.15 | $18.66 | $0.19 | $0.00 | $0.00 |
| 2012 | $28.18 | $49.25 | $21,639.92 | $0.00 | $0.00 |
| 2013 | $74.43 | $61.70 | $199,211.87 | $0.00 | $0.00 |
| 2014 | $92.90 | $116.01 | $2,799,997.98 | $2.24 | $0.00 |
| 2015 | $52.38 | $92.74 | $18,765.04 | $5.39 | $1.68 |
| 2016 | $46.65 | $134.42 | $339.74 | $0.00 | $0.00 |
| 2017 | $31.90 | $41.62 | $4.53 | $0.28 | $0.00 |
| 2018 | $36.47 | $41.18 | $6.02 | $6.28 | $0.00 |
| 2019 | $40.12 | $61.53 | $5.12 | $4.83 | $0.00 |
| 2020 | $73.47 | $111.71 | $12.06 | $29.24 | $34.25 |
| 2021 | $71.00 | $55.18 | $13.93 | $17.96 | $31.30 |
| 2022 | $40.05 | $45.78 | $4.02 | $15.19 | $10.60 |
| 2023 | $31.41 | $81.22 | $2.06 | $19.83 | $8.42 |
| 2024 | $23.37 | $34.68 | $4.68 | $6.07 | $0.00 |
| 2025 | $21.28 | $51.98 | $0.37 | $18.10 | $6.94 |
AI valuation
Our deep-learning model estimates Pacira BioSciences, Inc.'s (PCRX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $51.98
- Current price
- $24.44
- AI upside
- +112.68%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$8.51
-65.18% upside
Graham-Dodd
$18.10
-25.96% upside
Graham Formula
$6.94
-71.61% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| PCRX | Pacira BioSciences, Inc. | $24.44 | 942.6M | +113% | -65% | -26% | -72% | 134.83 | 1.37 | 1.31 | 6.38 | — | 3.11 | 71.50% | 2.64% | 3.68% | 0.96% | 2.60% | 0.50% | 0.01 | 1.10 | 4.54 | 2.34 | -1.19 | -10744.00% | 363.00% | -2355.00% | 14.41% | 1.26 | 18.51% | 0.00% | 0.00% | 53.86% | 41.67 | 5.85 | 1.10 | 1.80 |
| ANAB | AnaptysBio, Inc. | $55.05 | 1.52B | -23% | +23,485% | — | — | -3.19 | 6.54 | 5.08 | -4.83 | — | 6.54 | -79.49% | -125.93% | -159.10% | -182.71% | 99.94% | -31.02% | 5.21 | -2.29 | 9.51 | 9.38 | -2.66 | -1579.00% | 43203.00% | 1158.00% | -29.26% | -2.98 | 117.98% | 0.00% | 0.00% | 0.10% | -3.90 | -3.30 | 4.91 | -1.16 |
| BBOT | BridgeBio Oncology Therap… | $10.03 | 802.29M | — | — | — | — | 23.73 | 0.96 | — | -2.21 | — | 0.96 | 0.00% | — | — | 8.06% | -86.47% | 7.80% | 0.00 | — | 10.40 | 9.05 | 0.02 | -2310000.00% | — | — | -0.42% | -4.07 | -0.82% | 0.00% | 0.00% | 0.98% | -2.21 | -233.87 | — | 17.57 |
| CRON | Cronos Group Inc. | $2.67 | 1.02B | +1,212% | -39% | -5% | — | — | 0.93 | 5.24 | -12.20 | — | 0.99 | 32.46% | -1.51% | -4.89% | 0.00% | -0.69% | 0.00% | 0.00 | — | 19.59 | 18.88 | 52.68 | -12227.00% | 6440.00% | -9734.00% | 0.01% | 0.55 | 0.06% | 0.00% | — | 0.98% | -62.50 | 1207.50 | 0.95 | 12.80 |
| KOD | Kodiak Sciences Inc. | $26.80 | 1.42B | — | — | — | — | -1.08 | 1.27 | — | -0.62 | — | 1.27 | 0.00% | — | — | -84.70% | -174.25% | -43.24% | 0.47 | — | 6.72 | 6.57 | 0.65 | -3260.00% | — | -3982.00% | -61.84% | -4.59 | -109.78% | 0.00% | 0.00% | 0.00% | -0.50 | -0.79 | — | -6.24 |
| MNMD | Mind Medicine (MindMed) I… | $17.47 | 1.32B | — | — | — | — | -4.43 | 1.99 | — | -2.21 | — | 2.17 | — | — | — | -68.01% | 1162.37% | -50.94% | 0.09 | -45.52 | 7.25 | 7.05 | 2.42 | -9385.00% | — | 2294.00% | -16.44% | -2.04 | 885.11% | 0.00% | 0.00% | 34.56% | -2.21 | -2.90 | — | 2.74 |
| OCS | Oculis Holding AG | $29.41 | 1.68B | — | — | — | — | -7.08 | 8.29 | 886.66 | -7.02 | — | 10.12 | -7492.27% | -10671.14% | -12503.94% | -102.85% | 682.30% | -73.23% | 0.02 | — | 2.37 | 2.25 | 0.36 | -2862.00% | — | -1144.00% | -7.85% | -1.07 | 445.69% | 0.00% | 0.00% | 0.00% | -6.98 | -10.70 | 744.55 | 3.05 |
| PHAT | Phathom Pharmaceuticals, … | $12.56 | 979.85M | +275% | +76,266% | — | — | -3.78 | -1.91 | 4.77 | -4.45 | — | -1.91 | 87.09% | -91.36% | -126.35% | 63.97% | 57.00% | -69.41% | -0.01 | -2.35 | 1.73 | 1.58 | 0.80 | -4272.00% | 21693.00% | -3743.00% | -19.98% | -1.26 | 59.50% | 0.00% | 0.00% | 46.07% | -4.43 | -4.24 | 4.05 | -8.21 |
| TNDM | Tandem Diabetes Care, Inc… | $25.30 | 1.72B | +78% | -60% | — | — | -8.29 | 10.94 | 1.67 | -10.59 | -7.76 | 10.94 | 52.31% | -7.70% | -20.17% | -97.88% | -25.81% | -22.15% | 2.86 | -9.88 | 2.55 | 1.89 | -2.03 | 10680.00% | 793.00% | -69409.00% | -1.75% | -0.04 | -9.80% | 0.00% | 0.00% | 2.97% | -23.67 | -62.33 | 1.82 | 0.78 |
| URGN | UroGen Pharma Ltd. | $21.70 | 1.02B | -0% | -82% | — | — | -3.32 | -47.83 | 4.66 | -3.23 | — | -47.83 | 90.18% | -107.06% | -140.35% | 342.83% | 86.07% | -54.68% | -14.02 | -7.73 | 6.01 | 5.59 | 0.51 | -1662.00% | 929.00% | 2676.00% | -23.05% | -2.11 | 86.32% | 0.00% | 0.00% | 12.59% | -3.18 | -3.17 | 3.40 | -2.93 |
| XNCR | Xencor, Inc. | $12.77 | 911.91M | +93% | -51% | -81% | — | -9.93 | 1.44 | 7.27 | -15.55 | — | 1.46 | 91.63% | -141.35% | -73.20% | -14.00% | -41.06% | -10.06% | 0.40 | -5.56 | 6.25 | 4.84 | -4.22 | -6536.00% | 1365.00% | -3362.00% | -15.14% | -1.41 | -31.98% | 0.00% | 0.00% | 0.00% | -4.11 | -5.28 | 5.82 | 1.18 |
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
- CEO
- Frank D. Lee
- Employees
- 788
- Beta
- 0.25
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($8.51 ÷ $24.44) − 1 = -65.18% (DCF, example).